Heparin lowers plasma levels of activated factor VII

1999 ◽  
Vol 105 (4) ◽  
pp. 1127-1129 ◽  
Author(s):  
Thomas Pernerstorfer ◽  
Bernd Jilma ◽  
Hans-Georg Eichler ◽  
Susanne Aull ◽  
Sylvia Handler ◽  
...  
Keyword(s):  
Plasma Levels ◽  
Factor Vii ◽  
Activated Factor Vii

scholarly journals Activation of the coagulation cascade after infusion of a factor XI concentrate in congenitally deficient patients

Blood ◽  
1994 ◽  
Vol 84 (4) ◽  
pp. 1314-1319
Author(s):  
PM Mannucci ◽  
KA Bauer ◽  
E Santagostino ◽  
E Faioni ◽  
S Barzegar ◽  
...  
Keyword(s):  
Plasma Levels ◽  
Factor Ix ◽  
Coagulation Cascade ◽  
Factor Vii ◽  
Factor Xi ◽  
Factor Xi Deficiency ◽  
Activated Factor Vii ◽  
Before And After ◽  
Post Infusion ◽  
Secondary Hyperfibrinolysis

Virally inactivated, high-purity factor XI concentrates are available for treatment of patients with factor XI deficiency. However, preliminary experience indicates that some preparations may be thrombogenic. We evaluated whether a highly purified concentrate produced signs of activation of the coagulation cascade in two patients with severe factor XI deficiency infused before and after surgery. Signs of heightened enzymatic activity of the common pathway of coagulation (elevated plasma levels of prothrombin fragment 1 + 2 and fibrinopeptide A) developed in the early post-infusion period, accompanied by more delayed signs of fibrin formation with secondary hyperfibrinolysis (elevated D-dimer and plasmin-antiplasmin complex). These changes occurred in both patients, but were more severe in the older patient with breast cancer when she underwent surgery, being accompanied by fibrinogen and platelet consumption. There were no concomitant signs of heightened activity of the factor VII-tissue factor mechanism on the factor Xase complex (plasma levels of activated factor VII and of factor IX and X activation peptides did not increase). The observed changes in biochemical markers of coagulation activation indicate that concentrate infusions increased thrombin generation and activity and that such changes were magnified by malignancy and surgery. Because some factor XI concentrates may be thrombogenic, they should be used with caution, especially in patients with other risk factors for thrombosis.

Activation of the coagulation cascade after infusion of a factor XI concentrate in congenitally deficient patients

Blood ◽  
1994 ◽  
Vol 84 (4) ◽  
pp. 1314-1319 ◽  
Author(s):  
PM Mannucci ◽  
KA Bauer ◽  
E Santagostino ◽  
E Faioni ◽  
S Barzegar ◽  
...  
Keyword(s):  
Plasma Levels ◽  
Factor Ix ◽  
Coagulation Cascade ◽  
Factor Vii ◽  
Factor Xi ◽  
Factor Xi Deficiency ◽  
Activated Factor Vii ◽  
Before And After ◽  
Post Infusion ◽  
Secondary Hyperfibrinolysis

Abstract Virally inactivated, high-purity factor XI concentrates are available for treatment of patients with factor XI deficiency. However, preliminary experience indicates that some preparations may be thrombogenic. We evaluated whether a highly purified concentrate produced signs of activation of the coagulation cascade in two patients with severe factor XI deficiency infused before and after surgery. Signs of heightened enzymatic activity of the common pathway of coagulation (elevated plasma levels of prothrombin fragment 1 + 2 and fibrinopeptide A) developed in the early post-infusion period, accompanied by more delayed signs of fibrin formation with secondary hyperfibrinolysis (elevated D-dimer and plasmin-antiplasmin complex). These changes occurred in both patients, but were more severe in the older patient with breast cancer when she underwent surgery, being accompanied by fibrinogen and platelet consumption. There were no concomitant signs of heightened activity of the factor VII-tissue factor mechanism on the factor Xase complex (plasma levels of activated factor VII and of factor IX and X activation peptides did not increase). The observed changes in biochemical markers of coagulation activation indicate that concentrate infusions increased thrombin generation and activity and that such changes were magnified by malignancy and surgery. Because some factor XI concentrates may be thrombogenic, they should be used with caution, especially in patients with other risk factors for thrombosis.

Increased Levels of Activated Factor VII and Decreased Plasma Protein S Activity and Circulating Thrombomodulin during Use of Oral Contraceptives

1996 ◽  
Vol 76 (05) ◽  
pp. 729-734 ◽  
Author(s):  
Peter Quehenberger ◽  
Uta Loner ◽  
Stylianos Kapiotis ◽  
Sylvia Handler ◽  
Barbara Schneider ◽  
...  
Keyword(s):  
Blood Coagulation ◽  
Plasma Protein ◽  
Plasma Levels ◽  
Protein S ◽  
Factor Vii ◽  
Activation Markers ◽  
Treatment Groups ◽  
Activated Factor Vii ◽  
Inhibitory Components ◽  
Protein S Activity

SummaryIn the present study the effect of oral contraceptive (OC) treatment on selected factors involved in the activation, i.e. circulating activated factor VII (cFVIIa), and in the inhibition of blood coagulation, i.e. plasma protein S activity and circulating thrombomodulin (cTM), were for the first time measured in OC users in a prospective study. Beside other coagulation variables, these parameters were measured during treatment with three low estrogen formulations containing different gestagen components (norgestimate, gestodene). During OC treatment increases in the activation markers prothrombin fragment F1+2 and D-Dimer were found, suggesting an increased activation of blood coagulation and fibrinolysis. Along with elevated plasma levels of FVII antigen, cFVIIa was also found increased in all three treatment groups, while inhibitory components of blood coagulation, plasma protein S activity and cTM, significantly and similarily decreased during treatment in all three treatment groups. We conclude that low dose estrogen pills induce similar changes in the plasma levels of main regulatory components of blood coagulation, despite differences in their gestagen components. Increased levels of activators and decreased activities of inhibitors may contribute to arterial and venous thrombotic complications seen in predisposed OC users.

Marked Increase of Activated Factor VII in Uremic Patients

1995 ◽  
Vol 73 (05) ◽  
pp. 763-767 ◽  
Author(s):  
Kazuomi Kario ◽  
Takefumi Matsuo ◽  
Miyako Matsuo ◽  
Masanobu Koide ◽  
Tsutomu Yamada ◽  
...  
Keyword(s):  
Renal Function ◽  
Endothelial Cell ◽  
Tissue Factor ◽  
Plasma Levels ◽  
Cell Injury ◽  
Factor Vii ◽  
Control Group ◽  
Endothelial Cell Injury ◽  
Activated Factor Vii ◽  
Uremic Patients

SummaryWe investigated plasma activated factor VII (FVIIa) levels in uremic patients (nondialysis group: n = 38; dialysis group: n = 36) and healthy controls (n = 32). We also measured the plasma levels of thrombomodulin (an indicator of endothelial cell injury) and tissue factor. Plasma FVIIa showed a marked increase in the nondialysis group (mean [95% confidence interval]: 4.6 [4.1-5.1] ng/ml, p <0.0001) with the progressive impairment of renal function, as indicated by the serum creatinine level, when compared with the 32 controls (2.8 [2.5-3.1] ng/ml), and was further increased in the dialysis group (6.1 [5.5-6.8] ng/ml, p <0.001 vs. nondialysis group). Plasma levels of thrombomodulin and tissue factor were also higher in the nondialysis group than the control group, and were further increased in the dialysis group. Plasma tissue factor levels did not show any correlation with FVIIa or thrombomodulin in both the nondialysis and dialysis groups. Thus, circulating tissue factor appears to be released by a different mechanism from thrombomodulin and may not contribute to the direct activation of factor VII in uremic patients. On the other hand, the plasma level of thrombomodulin was positively correlated with that of FVIIa in the nondialysis group, and this correlation was independent of renal function. Thus, enhanced conversion of factor VII zymogen to FVIIa, probably related to endothelial cell injury, may be a risk factor for cardiovascular events in uremic patients.

scholarly journals Heightened Thrombin Formation but Normal Plasma Levels of Activated Factor VII in Patients With Acute Coronary Syndromes

1995 ◽  
Vol 15 (10) ◽  
pp. 1675-1679 ◽  
Author(s):  
Piera Angelica Merlini ◽  
Diego Ardissino ◽  
Luigi Oltrona ◽  
Marco Broccolino ◽  
Raffaella Coppola ◽  
...  
Keyword(s):  
Plasma Levels ◽  
Acute Coronary Syndromes ◽  
Factor Vii ◽  
Activated Factor Vii ◽  
Normal Plasma ◽  
Coronary Syndromes ◽  
Thrombin Formation

Decreased plasma levels of activated factor VII in patients with deep vein thrombosis

2015 ◽  
Vol 13 (7) ◽  
pp. 1320-1324 ◽  
Author(s):  
A. M. Schut ◽  
J. C. M. Meijers ◽  
Y. Lisman- van Leeuwen ◽  
M. L. van Montfoort ◽  
M. Roest ◽  
...  
Keyword(s):  
Deep Vein Thrombosis ◽  
Plasma Levels ◽  
Factor Vii ◽  
Vein Thrombosis ◽  
Activated Factor Vii ◽  
Deep Vein

Very Low Activated Factor VII and Reduced Factor VII Antigen in Familial Abetalipoproteinaemia

1998 ◽  
Vol 80 (08) ◽  
pp. 233-238 ◽  
Author(s):  
K. A. Mitropoulos ◽  
M. N. Nanjee ◽  
D. J. Howarth ◽  
J. C. Martin ◽  
M. P. Esnouf ◽  
...  
Keyword(s):  
Plasma Concentrations ◽  
Positive Association ◽  
Factor Ix ◽  
Factor Vii ◽  
Unesterified Fatty Acid ◽  
Factor Xii ◽  
Factor X ◽  
Factor Xi ◽  
Activated Factor Vii ◽  
Normal Mean

SummaryAbetalipoproteinaemia is a rare disorder of apolipoprotein B metabolism associated with extremely low plasma concentrations of triglyce-ride. To discover whether the general positive association between factor VII and triglyceride levels extends to this condition, 5 patients were compared with 18 controls. All patients had a triglyceride below 100 μmol/l. Plasma unesterified fatty acid concentration was normal. Although factor IX activity was only slightly reduced (mean 88% standard) and factor IX antigen was normal, mean activated factor VII in patients was strikingly reduced to 34% of that in controls, a level similar to that found in haemophilia B. The patients’ mean factor VII activity and factor VII antigen were also significantly reduced to 54% and 63% of those in controls, respectively. Mean factor XI activity and tissue factor pathway inhibitor activity were reduced in patients to 70% and 75% of control values respectively, while factor XII, factor XI antigen, factor X, prothrombin and protein C were normal.

The Strong Positive Correlation between Factor VII Clotting Activity Using Bovine Thromboplastin and the Activated Factor VII Level

1995 ◽  
Vol 73 (03) ◽  
pp. 429-434 ◽  
Author(s):  
Kazuomi Kario ◽  
Takefumi Matsuo ◽  
Reiko Asada ◽  
Toshiyuki Sakata ◽  
Hisao Kato ◽  
...  
Keyword(s):  
Risk Factor ◽  
Bovine Brain ◽  
Factor Vii ◽  
Rabbit Brain ◽  
Strong Positive Correlation ◽  
Chromogenic Substrate ◽  
Moderate Correlation ◽  
Positive Correlation ◽  
Activated Factor Vii

SummaryWe compared factor VII clotting activity (FVIIc) assays using different thromboplastins to determine which is the most sensitive for activated FVII (FVIIa) or for FVII antigen (FVIIag). FVIIc levels were measured using thromboplastins derived from bovine brain (FVIIc Bov), human placenta (FVIIc Hum), and rabbit brain (FVIIc Rab). FVIIa levels were measured by fluorogenic assays using human soluble tissue factor (rsTF) or bovine rsTF. We also measured FVII activity by an amidolytic assay (FVIIc:am Hum) using human thromboplastin and a chromogenic substrate for thrombin. FVIIag levels were determined by ELISA. In the FVIIa assay, the reaction time obtained from using bovine rsTF was shorter than that with human rsTF, suggesting that the interaction of plasma FVIIa with bovine rsTF was stronger than with human rsTF. The plasma FVIIa levels measured using human rsTF and bovine rsTF were almost the same (r=0.947, p<0.0001). Among the three FVIIc assays, FVIIc Bov had the strongest positive correlation with the plasma FVIIa level (r=0.886, p<0.000l), but had no correlation with FVIIag. An increase of 1 ng/ml in the plasma FVIIa level yielded a 27.9% increase of FVIIc Bov. Plasma FVIIc Hum and FVIIc:am Hum showed moderate correlations with both FVIIa (r=0.520, p<0.02 and r=0.569, p<0.01, respectively) and FVIIag (r=0.438, p<0.05 and r=0.468, p<0.05, respectively). FVIIc Rab had the lowest correlation with FVIIa (r=0.367, p<0.1), but had a moderate correlation with FVIIag (r=0.436, p<0.05). After in vitro cold activation, FVIIc Bov levels increased the most and FVIIc:am levels showed the least change. These findings indicate that consideration of the thromboplastin used for assay is necessary when assessing the clinical significance of FVII activity as a cardiovascular risk factor.

Sign in / Sign up

Export Citation Format

Share Document